Results per Page:
Giving CAR T cells a portable pit crew
Fred Hutch scientists dig deep into the biology of CAR T-cell exhaustion and examine experimental strategy to improve the immunotherapy for solid tumors
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
February 27, 2026
Extramedullary disease shapes toxicity risk in BCMA CAR T therapy
From the Gauthier Group, Clinical Research Division
Giving CAR T a second life in osteosarcoma
From the Meshinchi Lab, Clinical Research Division and Translational Science and Therapeutics Division
Understanding Parkinsonism after CAR T therapy
From Drs. John Sanderson, Kimmy Su, Anny Lin, and Yujie Wang, University of Washington Department of Neurology and Dr. Rahul Banerjee, Clinical Research Division
Made to last: engineering durable CAR-T cells
From the Peterson and Kiem Labs, Translational Science and Therapeutics Division
Guiding the attack: CXCR3 leads CAR T cells to pediatric brain tumors
From the Vitanza Lab, Seattle Children’s Research Institute, University of Washington and the Cancer Consortium
For many blood cancer patients, CAR T-cell therapy is game-changing
In this episode of From Bench to Bedside and Beyond, Dr. Mazyar Shadman explains why CAR T-cell therapy should be considered for patients who relapse
Gratitude for life-saving care at Fred Hutch leads to endowed chair
Dr. Madhav Dhodapkar is the recipient of the Milton B. Rubin Family Endowed Chair
‘Manufacturing scientist’ believes in the machinery that powers Fred Hutch’s cell therapies
Dr. Folashade Otegbeye is the recipient of the Fleischauer Family Endowed Chair in Cell and Gene Therapy Translation
A tale of two T-cells: comparing liso-cel and axi-cel for treatment of refractory large B-cell lymphoma
From the Gauthier group, Clinical Research Division
Cytomegalovirus has an activity shift following CAR T-cell therapy
From the Hill Group, Vaccine and Infectious Disease and Clinical Research Divisions
Gene therapy delivery system successfully targets CD90+ hematopoietic stem cells in vivo
Fred Hutch laboratory research presented at the American Society of Gene and Cell Therapy’s annual meeting moves a promising approach one step closer to clinical trials
Multiple myeloma is treatable, not curable. Is that set to change?
Some experts believe a ‘functional cure’ is already within reach
Now you see them, now you don’t: Gene editing protects stem cells from CAR T therapy
From the Kiem lab, Translational Science and Therapeutics Division
Fred Hutch research shines at national oncology conference
Society for Immunotherapy of Cancer meeting features new discoveries on cancer-cell visualization, T-cell survival and new targets for solid tumors
New initiative bolsters Washington state life sciences
Fred Hutch researchers awarded over $4M in grants from the Washington Research Foundation
Location, location, location: where is key for CAR T-cell therapy
From the Walter lab, Translational Science and Therapeutics Division
Histone mark profiling identifies KLF7 as critical for CAR-T cell proliferation
From the Henikoff lab, Translational Science and Therapeutics and Basic Sciences Divisions